Valuation: Satellos Bioscience Inc.

Market Cap 196M 173M 161M 148M 277M 18.83B 281M 1.91B 746M 9.3B 737M 721M 32.13B P/E 2026 *
-5.41x
P/E 2027 * -5.77x
Enterprise Value 103M 90.26M 84.02M 77.16M 145M 9.85B 147M 999M 390M 4.86B 385M 377M 16.8B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.52%
Yield 2026 *
-
Yield 2027 * -
1 day-4.66%
1 week+13.48%
Current month+24.77%
1 month+30.39%
3 months+35.16%
6 months-17.29%
Current year+67.93%
1 week 11.81
Extreme 11.81
14.99
1 month 10.17
Extreme 10.17
14.99
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
18/6/26 Buy

Director

15,000 0.0720%
7/4/26 Option

Founder

108,630 0.7027%
7/4/26 Buy

Director

5,500 0.0356%
Change 5-day change 1-year change 3-year change Capi.($)
-4.66%+13.48%+97.92%+167.07% 196M
-1.24%+2.60%+52.40%+71.81% 56.19B
-0.27%+0.35%+40.26%+79.88% 54.83B
+1.97%-1.16%-21.00%-13.25% 23.04B
-2.05%-2.14%+0.75%+413.38% 22.7B
-0.21%-0.62%+20.56%-10.90% 20.23B
-1.00%+1.81%+25.94%-30.33% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
+5.29%+1.70%+185.09%+333.94% 15.24B
+0.79%+0.50%+22.39%+184.74% 14.03B
Average -0.25%+2.14%+45.74%+174.70% 23.99B
Weighted average by Cap. -0.14%+1.08%+38.49%+137.81%

Financials

2026 *2027 *
Net sales - -
Net income -48.32M -42.48M -39.54M -36.32M -68.19M -4.63B -69.09M -470M -184M -2.29B -181M -177M -7.91B -56.57M -49.73M -46.29M -42.51M -79.83M -5.42B -80.88M -550M -215M -2.68B -212M -208M -9.26B
Net Debt -93.65M -82.33M -76.64M -70.38M -132M -8.98B -134M -911M -356M -4.43B -352M -344M -15.33B -111M -97.89M -91.12M -83.68M -157M -10.68B -159M -1.08B -423M -5.27B -418M -409M -18.22B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
27/07/26 CAD 13.30 -4.66% 23,688
24/07/26 CAD 13.95 +1.90% 25,832
23/07/26 CAD 13.69 +0.29% 42,982
22/07/26 CAD 13.65 +14.71% 21,994
21/07/26 CAD 11.90 +1.54% 24,820
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.30CAD
Average target price
17.67CAD
Spread / Average Target
+32.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock